MorphoSys AG (0NDV.L)
| Previous close | 22.32 |
| Open | 22.31 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 22.31 - 22.39 |
| 52-week range | 11.84 - 32.37 |
| Volume | |
| Avg. volume | 31,216 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
Business WireMorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
Business WireMorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
PLANEGG/MUNICH, Germany, December 11, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
